RedHill maintains a debt-free balance sheet with
$51 million cash1 at the end of the second quarter of
2017
Select recent milestones include:
·
Initial net revenues of
approximately $0.5 million between June 12-30 following commencement of
promotional activities in the U.S. by RedHill’s GI-focused sales force with two
GI specialty products, Donnatal® and EnteraGam®
·
Positive top-line results from
the Phase III GUARD study with BEKINDA® (RHB-102) 24 mg for
acute gastroenteritis and gastritis
·
Initiation of the confirmatory
Phase III study with TALICIA™ (RHB-105) for the treatment
of H. pylori infection
·
Last patient out in the Phase
II study with BEKINDA® 12 mg for
IBS-D
·
Orphan Drug designation
granted to YELIVA® (ABC294640) for the treatment of
cholangiocarcinoma
Select potential milestones expected in the second
half of 2017:
·
Second independent DSMB
meeting of the RHB-104 first Phase III study for Crohn’s disease, including an
interim efficacy analysis and an evaluation of an option for early stop for
success for overwhelming efficacy; DSMB recommendation is expected to be
announced by early August 2017
·
Top-line results from the
BEKINDA® 12 mg Phase II study for IBS-D, expected in September
2017
·
Type B FDA meeting regarding
the successful Phase III GUARD study with BEKINDA® 24 mg,
expected by October 2017
·
Initiation of several Phase Ib
and Phase II studies with YELIVA® for cholangiocarcinoma,
mucositis in head and neck cancer and ulcerative colitis, and with MESUPRON for
pancreatic cancer
·
Re-submission of the RIZAPORT® NDA
to the FDA, expected in October 2017
TEL-AVIV, Israel and RALEIGH, N.C., July 26 (GLOBE
NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv
Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty
biopharmaceutical company primarily focused on late clinical-stage development
and commercialization of proprietary, orally-administered, small molecule drugs
for gastrointestinal and inflammatory diseases and cancer, today reported its
financial results for the quarter ended June 30, 2017.
Company contact:
Adi Frish
Senior VP Business
Development &
Licensing
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
IR contact (U.S.):
Marcy Nanus
Senior Vice
President
The Trout Group
+1-646-378-2927
Mnanus@troutgroup.com
SOURCE : RedHill Biopharma Ltd.
No comments:
Post a Comment